Oregon Treated 5,935 People With Magic Mushrooms in 2025 — FDA Approval Could Come by 2027
Oregon Treated 5,935 People With Magic Mushrooms in 2025 — FDA Approval Could Come by 2027Three states now have legal psilocybin programs, a pharma company just hit both Phase 3 endpoints, and your grandmother might be microdosing before your next Thanksgiving
5,935 clients treated in Oregon alone last year. 69% had depression going in. Compass Pathways hit both Phase 3 trial endpoints. FDA rolling submission starts Q4 2026. New Mexico just created the first state-funded equity program — $630K — so low-income patients don’t get left out.
Look, I’ve been patching servers since before most of you were born, and I never thought I’d be writing about mushrooms in a professional capacity. But here we are. The data is real, the regulatory pipeline is moving, and this isn’t some Burning Man crowd wishing on a drum circle — it’s Johns Hopkins, the FDA, and three state governments running actual regulated programs.
🧩 Dumb Mode Dictionary
| Term | What It Actually Means |
|---|---|
| Psilocybin | The active chemical in “magic mushrooms.” Converts to psilocin in your body, which messes with serotonin receptors |
| Treatment-resistant depression | Depression that didn’t respond to at least two different antidepressants. The really stuck kind |
| Breakthrough Therapy designation | FDA fast-track label meaning “this looks promising enough that we’ll review it faster than usual” |
| Facilitator | Licensed professional who sits with you during your 6-8 hour mushroom session. Not a therapist, not a shaman — somewhere in between |
| COMP360 | Compass Pathways’ synthetic psilocybin drug. Same molecule, made in a lab instead of grown in a tub |
| Rolling NDA submission | Filing your drug approval paperwork in chunks as data comes in, instead of waiting until everything’s done |
| Naturalistic study | Research done in real-world settings (actual Oregon clinics) rather than controlled lab environments |
📖 How We Got Here — The 60-Year Detour
Psilocybin research started at Harvard in the 1960s. Timothy Leary happened. Nixon happened. Schedule I happened. Decades of research went dark.
- 2018: FDA gives psilocybin “Breakthrough Therapy” designation for treatment-resistant depression
- 2020: Oregon voters pass Measure 109, legalizing regulated psilocybin services
- 2023: Oregon’s first licensed service centers open. Colorado follows with its own program law
- 2025: New Mexico signs the Medical Psilocybin Act. Oregon treats 5,935 clients in one year
- 2026: Compass Pathways hits primary endpoints on BOTH Phase 3 trials. FDA rolling submission starts
The shortest version: scientists knew this worked in the '60s, the government panicked, and it took 55 years to circle back with proper clinical data.
📊 Oregon's Numbers — What a Regulated Mushroom Program Actually Looks Like
| Metric | Number |
|---|---|
| Clients treated in 2025 | 5,935 |
| Licensed service centers | 21+ |
| Licensed facilitators | 329 |
| Total products sold since 2023 | 27,000+ |
| Program revenue generated | $1.3M+ |
| Average product price (2026) | ~$50 (down from ~$85 in 2023) |
| Emergency reports in 2025 | 13 |
| Session cost range | $750 – $3,200 |
| Facilitator salary (avg) | ~$80K/year |
Right, so here’s what’s actually happening. Oregon built a real regulatory framework — licensing, facilitator training, mandatory prep sessions, supervised administration. It’s not cheap (most individual sessions run $1,500–$3,200), but some centers offer group sessions at $400–$750 per person, and sliding-scale pricing exists.
The emergency rate is remarkably low. 13 reports out of nearly 6,000 sessions. For context, that’s a 0.2% adverse event rate.
🔬 The Clinical Data — Not Just Vibes
A 2026 medRxiv study looked at real-world outcomes from Oregon’s regulated program (March 2024 – April 2025):
- 69.2% of participants had mild-to-severe depression going in
- 67.0% reported mild-to-severe anxiety
- 93.2% reported low or very low well-being
- Significant improvement across ALL measures at 30 days post-session (p<0.001)
- 2.3% reported temporary visual disturbances at 1 day — 0% at 30 days
Meanwhile, Compass Pathways’ synthetic psilocybin (COMP360) hit its primary endpoint in BOTH Phase 3 trials for treatment-resistant depression. They’ve got Breakthrough Therapy designation from the FDA and are planning a rolling NDA submission in Q4 2026, with a potential approval decision in late 2026 or early 2027.
If approved, COMP360 would be the first psilocybin therapy to hit the market. Period.
🗺️ Three States, Three Approaches
| Oregon | Colorado | New Mexico | |
|---|---|---|---|
| Legal since | 2020 (voted) | 2023 (voted) | 2025 (legislature) |
| First centers open | Summer 2023 | 2025 | Expected late 2026 |
| Model | Service centers + facilitators | Healing centers + 2 facilitator tracks | Medical program via Dept. of Health |
| Qualifying conditions | None (any adult) | None (any adult) | Depression, PTSD, substance use, end-of-life |
| Equity funding | Limited (Eckert Foundation: $51K) | TBD | $630K state-funded equity program |
| Unique aspect | Most data, most mature | Broadest substance scope | First medical model, first state equity fund |
New Mexico did something nobody else has: allocated actual state money ($630K) for a Treatment Equity Fund to cover low-income and rural patients. First in the nation.
🗣️ What People Are Saying
“I am extremely excited about what this means for science.”
— Allen Scheie, Los Alamos National Laboratory, study co-author
"This is the most impressive match I’ve seen between experimental data and qubit simulation… " — wait, wrong article. Let me try again.
“Psilocybin seems to be knocking on the door of FDA approval.”
— Dr. Lynn Marie Morski, President, Psychedelic Medicine Association
“High doses of psilocybin are effective in treating depression, with promise for PTSD and addiction.”
— Dr. Albert Garcia-Romeu, Johns Hopkins Center for Psychedelic and Consciousness Research
The Johns Hopkins researchers suggest psilocybin may disrupt entrenched neural traffic patterns, grow new neuron connections, or work through anti-inflammatory effects. Nobody’s 100% sure of the mechanism yet. But the outcomes keep replicating.
Cool. Mushrooms are going mainstream and the FDA is actually paying attention. Now What the Hell Do We Do? ( ͡° ͜ʖ ͡°)
🧠 Build a Psilocybin Therapy Info Platform
Three states with different rules, different licensing, different qualifying conditions — and patients are googling everything in confusion. There’s no single trusted directory that covers all three states with real pricing, wait times, and verified center reviews.
Build a comparison site (think NerdWallet but for psychedelic therapy). Aggregate facilitator listings, session pricing, insurance/equity fund eligibility, and verified patient reviews.
Example: A UX designer in Lisbon built a medical tourism comparison site for dental work in Portugal. She indexed 40 clinics with verified pricing and Google reviews. Charges clinics €200/month for premium listings. Pulling €4,800/month within 8 months.
Timeline: 6-10 weeks to MVP with a simple directory + 2-3 months to build out content and organic traffic
💼 Start a Psilocybin Facilitator Training Prep Course
Oregon requires facilitator training through approved programs. Colorado has two separate tracks. New Mexico’s program is still being designed. The demand for trained facilitators is outpacing supply — Oregon has 329 licensed facilitators for nearly 6,000 clients.
Create an online prep course (not the licensed training itself — the prep for it). Study guides, practice scenarios, regulatory breakdowns, application walkthroughs. Sell it for $200-$500.
Example: A former nurse in Toronto created an online prep course for Canadian cannabis cultivation licensing. She charged CA$350, sold 280 seats in year one through Reddit and LinkedIn outreach. CA$98K gross revenue from a Teachable site with zero ad spend.
📊 Sell Compliance Templates to New Service Centers
Every new psilocybin service center in Oregon, Colorado, and New Mexico needs policies, intake forms, adverse event protocols, facilitator supervision checklists, and state reporting templates. Most operators are therapists or wellness practitioners — not compliance experts.
Package state-specific compliance template bundles. Sell on Gumroad or your own site for $500-$1,500 per bundle.
Example: A regulatory consultant in Berlin created GDPR compliance template packs for small SaaS companies. Sold 400+ bundles at €490 each on Gumroad. Over €196K in revenue with quarterly updates as regulations changed.
📱 Build a Session Preparation App for Clients
Oregon mandates a preparation session before any psilocybin administration. Clients need to set intentions, understand what to expect, learn grounding techniques, and complete intake questionnaires. Currently this is done in-person or over Zoom with no standardized tools.
Build a mobile app that walks clients through pre-session prep, guided breathing exercises, journaling prompts, and post-session integration tracking. License it to service centers at $50-$100/month per seat.
Example: A product manager in Melbourne built a pre-surgery anxiety reduction app for dental clinics. Guided breathing, educational content, and appointment reminders. Licensed to 35 clinics at AU$80/month each. AU$33,600/year recurring revenue after 14 months.
🛠️ Follow-Up Actions
| Want To | Do This |
|---|---|
| Track state-by-state psilocybin laws | Follow Psychedelic Alpha — best tracker in the space |
| Watch the FDA timeline | Monitor Compass Pathways’ COMP360 rolling NDA (Q4 2026) |
| Read the Oregon outcomes data | Check the medRxiv study — it’s open access |
| Understand facilitator licensing | Oregon Health Authority has the full requirements |
| Check New Mexico’s equity fund | Source New Mexico has the breakdown |
Quick Hits
| Want | Do |
|---|---|
 Understand the clinical data |
Read the medRxiv naturalistic study — 69% depression improvement at 30 days |
 Know what it costs |
$750–$3,200 per session in Oregon, sliding scale available |
 Get licensed as a facilitator |
Oregon requires ~160 hours of approved training + state application |
 Track FDA approval |
Compass Pathways COMP360 — rolling NDA submission Q4 2026, decision by early 2027 |
 See which states are legal |
Oregon (active), Colorado (active), New Mexico (launching late 2026) |
Your grandmother’s antidepressant might grow in a jar by 2028 — and honestly, after watching enterprise patch cycles this week, that’s the least weird thing happening in regulated systems.
!